Digital health devices must prove a benefit to get reimbursement

13 May 2022 - Digital health care companies should prove that their devices can improve the quality of patient care ...

Read more →

Aadi Bioscience announces unique permanent J code issued for Fyarro from Centers for Medicare and Medicaid Services

4 May 2022 - Effective 1 July J code will enable a streamlined reimbursement process for Fyarro. ...

Read more →

UnitedHealthcare restricts coverage of Aduhelm, following Medicare

2 May 2022 - UnitedHealthcare is restricting insurance coverage of Aduhelm across all of its health plans, saying the drug ...

Read more →

Digital Medicine Society launches toolkit to support reimbursement for new drugs developed using digital outcomes

4 April 2022 - New essential resources ensure that patients will benefit without delay following regulatory acceptance of digital outcomes. ...

Read more →

Bluebird Bio has serious cash flow concerns; inability to strike reimbursement deals in Europe partly to blame

3 April 2022 - Bluebird bio is a highly innovative biotechnology company which develops gene therapies for several rare genetic ...

Read more →

Valeo Pharma secures additional public reimbursement for Redesca, Enerzair Breezhaler and Atectura Breezhaler

22 March 2022 - Canadian provincial public reimbursement now complete for Redesca with the addition of British Columbia. ...

Read more →

New hope offered to rare disease patients

14 December 2021 - Early this month, the world's first therapy to treat spinal muscular atrophy, a rare genetic disorder ...

Read more →

InnoCare announces inclusion of orelabrutinib in China National Reimbursement Drug List

2 December 2021 - InnoCare Pharma announced today that its BTK inhibitor orelabrutinib has been included in the updated National Reimbursement ...

Read more →

Zai Lab announces inclusion of Zejula (niraparib) in China’s National Reimbursement Drug List for first-line ovarian cancer

3 December 2021 - Zai Lab today announced that the National Reimbursement Drug List released by China’s National Healthcare Security Administration ...

Read more →

China clears insurance coverage for Kainos Medicine’s HIV drug

6 December 2021 - A home-grown HIV treatment developed by Kainos Medicine and out-licensed to China’s Jiangsu Aidea Pharmaceuticals has ...

Read more →

Ascletis announces inclusion in new catalogue of China National Reimbursement Drug List of Asclevir/Ganovo regimen, an all oral direct anti-HCV therapy

2 December 2021 - Ascletis Pharma today announces that its all-oral direct anti-hepatitis C virus Asclevir (ravidasvir)/Ganovo (danoprevir) regimen has been ...

Read more →

BeiGene announces inclusion in the China National Reimbursement Drug List (NRDL) of tislelizumab in three new indications, Brukinsa (zanubrutinib) in one new indication, and the first listing for pamiparib

2 December 2021 - BeiGene today announced that three of its medicines have been added to the most recent National Reimbursement ...

Read more →

Junshi Biosciences announces two additional indications for toripalimab included in China’s National Reimbursement Drug List

3 December 2021 - The only anti-PD-1 monoclonal antibody in the NRDL for melanoma and nasopharyngeal carcinoma. ...

Read more →

Drug makers cut prices by 62% on average to get China state insurance listing

4 December 2021 - Pharmaceutical firms have agreed to cut prices by 61.7% on average for 67 medicines to be ...

Read more →

CMS repeals MCIT/R&N rule; will consider other coverage pathways to enhance access to innovative medical devices

12 November 2021 - Today, CMS is rescinding the Medicare Coverage of Innovative Technology and Definition of “Reasonable and Necessary” (MCIT/R&N) ...

Read more →